Last reviewed · How we verify
Aliskiren plus Losartan
At a glance
| Generic name | Aliskiren plus Losartan |
|---|---|
| Also known as | Aliskiren plus Losartan group |
| Sponsor | Chulalongkorn University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Non-Inferiority Study of Aliskiren vs Losartan in the Treatment of Hypertension With Hyperuricemia (PHASE4)
- ACEI or ARB and COVID-19 Severity and Mortality in US Veterans
- Treatment of Supine Hypertension in Autonomic Failure (PHASE1)
- Safety and Efficacy of Aliskiren When Added to Standardized Losartan and Optimal Antihypertensive Therapy in Patients With Hypertension, Type 2 Diabetes and Proteinuria (PHASE2)
- Study Comparing SPP100 (Aliskiren) 150mg to Placebo and to Losartan 50mg in Patients With Mild to Moderate Essential Hypertension (PHASE3)
- Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade (PHASE4)
- Aliskiren Combined With Losartan in Proteinuric, Non-diabetic Chronic Kidney Disease (PHASE4)
- Influence of Aliskiren on Albuminuria After Kidney Transplantation (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Aliskiren plus Losartan CI brief — competitive landscape report
- Aliskiren plus Losartan updates RSS · CI watch RSS
- Chulalongkorn University portfolio CI